| A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression SB Polak, IC Van Gool, D Cohen, JH von der Thüsen, J van Paassen Modern Pathology 33 (11), 2128-2138, 2020 | 577 | 2020 |
| A panoply of errors: polymerase proofreading domain mutations in cancer E Rayner, IC Van Gool, C Palles, SE Kearsey, T Bosse, I Tomlinson, ... Nature Reviews Cancer 16 (2), 71-81, 2016 | 346 | 2016 |
| POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer IC van Gool, FA Eggink, L Freeman-Mills, E Stelloo, E Marchi, M de Bruyn, ... Clinical Cancer Research 21 (14), 3347-3355, 2015 | 307 | 2015 |
| A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer HH Workel, JM Lubbers, R Arnold, TM Prins, P van der Vlies, K de Lange, ... Cancer immunology research 7 (5), 784-796, 2019 | 168 | 2019 |
| Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for … FA Eggink, IC Van Gool, A Leary, PM Pollock, EJ Crosbie, L Mileshkin, ... Oncoimmunology 6 (2), e1264565, 2017 | 136 | 2017 |
| Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape … D Temko, IC Van Gool, E Rayner, M Glaire, S Makino, M Brown, ... The Journal of Pathology 245 (3), 283-296, 2018 | 98 | 2018 |
| Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer IC Van Gool, E Stelloo, RA Nout, HW Nijman, RJ Edmondson, DN Church, ... Modern pathology 29 (2), 174-181, 2016 | 92 | 2016 |
| Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues IC Van Gool, E Rayner, EM Osse, RA Nout, CL Creutzberg, ... Clinical Cancer Research 24 (13), 3197-3203, 2018 | 69 | 2018 |
| Blinded histopathological characterisation of POLE exonuclease domain‐mutant endometrial cancers: sheep in wolf's clothing IC Van Gool, JEH Ubachs, E Stelloo, CD de Kroon, JJ Goeman, VT Smit, ... Histopathology 72 (2), 248-258, 2018 | 48 | 2018 |
| POLE proofreading mutation, immune response and prognosis in endometrial cancer IC van Gool, T Bosse, DN Church Oncoimmunology 5 (3), e1072675, 2016 | 43 | 2016 |
| Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer M van Esterik, IC Van Gool, CD de Kroon, RA Nout, CL Creutzberg, ... Oncotarget 8 (15), 25542, 2017 | 19 | 2017 |
| Antineutrophil cytoplasmic antibodies in infective endocarditis: a case report and systematic review of the literature IC Van Gool, J Kers, JA Bakker, JI Rotmans, YKO Teng, MP Bauer Clinical Rheumatology 41 (10), 2949-2960, 2022 | 15 | 2022 |
| Neoepitopes and CD3-Positive and CD8-Positive Cells in Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers IC van Gool, T Bosse, DN Church JAMA oncology 2 (1), 141-141, 2016 | 5 | 2016 |
| Somatic POLE exonuclease domain mutations in endometrial cancer: Insights into the biology of POLE-mutant tumors IC Gool | | |
